<DOC>
	<DOCNO>NCT02925338</DOCNO>
	<brief_summary>National , prospective , multicentre observational study design eligible patient treat Inflectra . Its objective describe real condition use , profile patient treat Inflectra response treatment .</brief_summary>
	<brief_title>National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Adult patient treat Inflectra™ regardless treatment phase one follow indication consistent SPC : Crohn 's Disease , ulcerative colitis , rheumatoid arthritis , ankylose spondylitis psoriatic arthritis . Paediatric patient ( child adolescents 6 17 year old ) treat Inflectra™ , regardless treatment phase time Inflectra™ prescribe accordance indication list SPC Crohn 's Disease ulcerative colitis Patients ( legal representative ) receive information ( verbally write ) study agree take part . Patients give agreement clinical data medical file access sign information leaflet . Patients refuse access medical file collection : medical data Patients treat Inflectra™ . Patients treat Inflectra™ psoriasis . Patients past history hypersensitivity infliximab , murine proteins one excipients Inflectra™ . Patients tuberculosis severe infection sepsis , abscess opportunistic infection . Patients moderate severe heart failure ( NYHA III/IV )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>